Details of Drug

Details of Drug

 Drug General Information (ID: D0001)
  Drug Name
Abacavir
  Drug Type Small molecule
  Drug Synonymous
Trizivir; Ziagen; Abacavir [INN]; Abacavir (INN); Ziagen (TN); Ziagen (TM)(*Succinate salt*); [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol; {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; (+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; (+/-)-Abacavir; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ABC
    Click to Show/Hide
  Disease Class 1C60-1C62: Human immunodeficiency virus disease
  Therapeutic Class Anti-Hiv Agents
  Structure Could Not Find 2D Structure
3D Structure 2D Structure
  Formula C14H18N6O
  InChI 1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1
  InChIKey MCGSCOLBFJQGHM-SCZZXKLOSA-N
  Canonical SMILES C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO
  External Link
Pubchem ID 441300
CAS Number 136470-78-5
CHEBI ID 421707
TTD ID D0A4IJ
INTEDE ID DR0027
VARIDT ID DR00588

Drug-Drug Interaction Network
  Sunburst Graph
AM001  Affected gastrointestinal absorption
AM004  Affected intra/extra-hepatic metabolism
AM006  Pharmacodynamic additive effects
AM007  Pharmacodynamic antagonistic effects
BM009  Altered absorption (Unspecific)
BM017  CYP450 enzyme inhibition
BM018  Non-CYP450 enzyme inhibition
BM024  Competitive inhibition of metabolic enzyme
BM055  Increased risk of hepatotoxicity
BM070  Increased risk of metabolic acidosis
BM107  Attenuated pharmacological effects (Unspecific)
  Relation Graph
 Full list of drugs interacting with Abacavir
      Affected gastrointestinal absorption
   Altered absorption (Unspecific) Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1187
 
Orlistat
 
C29H53NO5
 
3034010 
Moderate    Inter Info   
[31]
      Affected intra/extra-hepatic metabolism
   CYP450 enzyme inhibition Drug Num:  2
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0375
 
Cobicistat
 
C40H53N7O5S2
 
25151504 
Moderate    Inter Info   
[10], [11], [22], [23], [24], [25], [26], [27], [28], [29]
D1408
 
Riociguat
 
C20H19FN8O2
 
11304743 
Moderate    Inter Info   
[1], [10], [11], [39]
   Non-CYP450 enzyme inhibition Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0617
 
Ethanol
 
C2H6O
 
702 
Minor    Inter Info   
[39]
   Competitive inhibition of metabolic enzyme Drug Num:  5
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0311
 
Chloral hydrate
 
C2H3Cl3O2
 
2707 
Minor    Inter Info   
[39]
D0324
 
Chlorpromazine
 
C17H19ClN2S
 
2726 
Minor    Inter Info   
[39]
D0327
 
Chlorzoxazone
 
C7H4ClNO2
 
2733 
Minor    Inter Info   
[39]
D0509
 
Disulfiram
 
C10H20N2S4
 
3117 
Minor    Inter Info   
[39]
D0858
 
Isoniazid
 
C6H7N3O
 
3767 
Minor    Inter Info   
[39]
      Pharmacodynamic additive effects
   Increased risk of hepatotoxicity Drug Num:  23
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0900
 
Leflunomide
 
C12H9F3N2O2
 
3899 
Major    Inter Info   
[1], [2], [3]
D0944
 
Lomitapide
 
C39H37F6N3O2
 
9853053 
Major    Inter Info   
[4]
D1073
 
Mipomersen
 
C230H324N67O122P19S19
 
118984467 
Major    Inter Info   
[5]
D1258
 
Pexidartinib
 
C20H15ClF3N5
 
25151352 
Major    Inter Info   
[6]
D1556
 
Teriflunomide
 
C12H9F3N2O2
 
54684141 
Major    Inter Info   
[1], [2], [3]
D0113
 
Asparaginase Erwinia chrysanthemi
 
NA
 
NA
Moderate    Inter Info   
[7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19]
D0199
 
Brentuximab vedotin
 
NA
 
NA
Moderate    Inter Info   
[20]
D0232
 
Calaspargase pegol
 
NA
 
NA
Moderate    Inter Info   
[7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19]
D0248
 
Cannabidiol
 
C21H30O2
 
644019 
Moderate    Inter Info   
[11], [21]
D0789
 
Idelalisib
 
C22H18FN7O
 
11625818 
Moderate    Inter Info   
[30]
D1239
 
Peginterferon beta-1a
 
NA
 
NA
Moderate    Inter Info   
[32], [33], [34], [35]
D1389
 
Remdesivir
 
C27H35N6O8P
 
121304016 
Moderate    Inter Info   
[10], [11], [36], [37], [38]
D1615
 
Trabectedin
 
C39H43N3O11S
 
108150 
Moderate    Inter Info   
[11], [40]
D0114
 
Asparaginase Escherichia coli
 
NA
 
NA
Moderate    Inter Info   
[7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19]
D0357
 
Clofarabine
 
C10H11ClFN5O3
 
119182 
Moderate    Inter Info   
[43]
D0554
 
Efavirenz
 
C14H9ClF3NO2
 
64139 
Moderate    Inter Info   
[44], [27]
D0584
 
Epirubicin
 
C27H29NO11
 
41867 
Moderate    Inter Info   
[10], [11], [45]
D0826
 
Interferon beta-1a
 
NA
 
NA
Moderate    Inter Info   
[32], [33], [34], [35]
D0827
 
Interferon beta-1b
 
NA
 
NA
Moderate    Inter Info   
[32], [33], [34], [35]
D1025
 
Methotrexate
 
C20H22N8O5
 
126941 
Moderate    Inter Info   
[11], [46]
D1106
 
Naltrexone
 
C20H23NO4
 
5360515 
Moderate    Inter Info   
[47]
D1234
 
Pegaspargase
 
C14H19NO
 
436058 
Moderate    Inter Info   
[7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19]
D1589
 
Tioguanine
 
C5H5N5S
 
2723601 
Moderate    Inter Info   
[51], [52]
   Increased risk of metabolic acidosis Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1397
 
Ribavirin
 
C8H12N4O5
 
37542 
Moderate    Inter Info   
[48], [49], [50]
      Pharmacodynamic antagonistic effects
   Attenuated pharmacological effects (Unspecific) Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0348
 
Cladribine
 
C10H12ClN5O3
 
20279 
Moderate    Inter Info   
[11], [41], [42]
References
1 Canadian Pharmacists Association.
2 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
3 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
4 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
5 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
6 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
7 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
8 Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub. [PMID: 16988508]
9 Cerner Multum, Inc "ANVISA Bulario Eletrnico.".
10 Cerner Multum, Inc. "Australian Product Information.".
11 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12 Christ TN, Stock W, Knoebel RW "Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen." J Oncol Pharm Pract 24 (2018): 299-308. [PMID: 28355969]
13 Jenkins R, Perlin E "Severe hepatotoxicity from Escherichia coli L-asparaginase." J Natl Med Assoc 79 (1987): 775-9. [PMID: 3305969]
14 Lu G, Karur V, Herrington JD, Walker MG "Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine" Proc (Bayl Univ Med Cent) 29 (2016): 46-7. [PMID: 26722167]
15 Product Information. Asparlas (calaspargase pegol). Servier, Boston, MA.
16 Product Information. Elspar (asparaginase). Merck & Co, Inc, West Point, PA.
17 Product Information. Erwinaze (asparaginase Erwinia chrysanthemi). EUSA Pharma, Newtown, PA.
18 Product Information. Oncaspar (pegaspargase). Rhone-Poulenc Rorer, Collegeville, PA.
19 Burke PW, Aldoss I, Lunning MA, et.al "High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles." Blood 122 (2013): 2671. [PMID: 29407583]
20 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
21 Product Information. Epidiolex (cannabidiol). Greenwich Biosciences Inc, Carlsbad, CA.
22 Product Information. Evotaz (atazanavir-cobicistat). Bristol-Myers Squibb, Princeton, NJ.
23 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
24 Product Information. Prezcobix (cobicistat-darunavir). Janssen Pharmaceuticals, Titusville, NJ.
25 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
26 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
27 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
28 Product Information. Tybost (cobicistat). Gilead Sciences, Foster City, CA.
29 Product Information. Viramune (nevirapine). Boehringer-Ingelheim, Ridgefield, CT.
30 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
31 MHRA. Medicines and Healthcare Products Regulatory Agency "Orlistat: theoretical interaction with antiretroviral HIV medicines.".
32 Product Information. Avonex (interferon beta-1a). Biogen, Cambridge, MA.
33 Product Information. Betaseron (interferon beta-1b). Berlex, Richmond, CA.
34 Product Information. Plegridy (peginterferon beta-1a). Biogen Idec Inc, Cambridge, MA.
35 Product Information. Rebif (interferon beta-1a). Serono Laboratories Inc, Norwell, MA.
36 European Medicines Agency "Summary on compassionate use. Remdesivir Gilead.".
37 Gilead Sciences, Inc "About Remdesivir.".
38 US Food and Drug Administration "Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM)".
39 Product Information. Ziagen (abacavir). Glaxo Wellcome, Research Triangle Pk, NC.
40 Product Information. Yondelis (trabectedin). Janssen Pharmaceuticals, Titusville, NJ.
41 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
42 Product Information. Leustatin (cladribine). Ortho Biotech Inc, Raritan, NJ.
43 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
44 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
45 Product Information. Ellence (epirubicin) Pharmacia and Upjohn, Kalamazoo, MI.
46 Product Information. Methotrexate (methotrexate). Lederle Laboratories, Wayne, NJ.
47 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
48 Guyader D, Poinsignon Y, Cano Y, Saout L "Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C." J Hepatol 37 (2002): 289-91. [PMID: 12127440]
49 Product Information. Copegus (ribavirin). Roche Laboratories, Nutley, NJ.
50 Product Information. Rebetron (interferon-alfa-2b-ribavirin). Schering Laboratories, Kenilworth, NJ.
51 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
52 Product Information. Tabloid (thioguanine). Prasco Laboratories, Cincinnati, OH.